Business Standard

Healthcare index nears all-time high, Sun Pharma zooms

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in EBITDA

Related News

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

The Healthcare index — which tracks the movement of pharma shares on the BSE —the largest gainer among the sectoral indices is up 70 points or 1% at 6,845, trading nears to its lifetime high of 6,871 touched on January 2011.

The index has outperforming by gaining 16.6% year-to-date, compared with 12.5% rise in the benchmark index Sensex.

Sun Pharma Industries is trading higher by 2% at Rs 607, extending its yesterday’s over 2% gain after a favourable verdict from the US Supreme Court in its patent case against Novo Nordisk.

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in earnings before interest, taxes, depreciation, and amortization (EBITDA) led by strong performance by Sun Pharma on the back of improvement in the profitability of Taro, and Cadila led by acquisitions, Glenmark Pharma and Torrent Pharma on a low base.

The research firm expects the sector will post a topline growth of 13.5% on year-on-year basis (excluding one-offs) and adjusted profit after tax (PAT) is expected to grow by 12.5% on YoY.

Read more on:   
|
|
|
|
|

Healthcare index nears all-time high, Sun Pharma zooms

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in EBITDA

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, Wockhardt and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

The Healthcare index — which tracks the movement of pharma shares on the BSE —the largest gainer among the sectoral indices is up 70 points or 1% at 6,845, trading nears to its lifetime high of 6,871 touched on January 2011.

The index has outperforming by gaining 16.6% year-to-date, compared with 12.5% rise in the benchmark index Sensex.

Sun Pharma Industries is trading higher by 2% at Rs 607, extending its yesterday’s over 2% gain after a favourable verdict from the US Supreme Court in its patent case against Novo Nordisk.

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in earnings before interest, taxes, depreciation, and amortization (EBITDA) led by strong performance by Sun Pharma on the back of improvement in the profitability of Taro, and Cadila led by acquisitions, Glenmark Pharma and Torrent Pharma on a low base.

The research firm expects the sector will post a topline growth of 13.5% on year-on-year basis (excluding one-offs) and adjusted profit after tax (PAT) is expected to grow by 12.5% on YoY.

image

Read More

Credit ratings fell the most in three years: CRISIL

According to CRISIL, the Indian arm of Standard & Poor which rates over 9,000 issuers in India, credit ratings have fallen the most in three ...

Recommended for you

Quick Links

Market News

Nickel rises by 0.1% on Asian cues

Traders strengthened positions amid a firming Asian cues

Oil prices rise further in Asia

Expectations of a decline in US crude inventories and robust economic data from the eurozone helped prices

Markets remain rangebound; HUL up over 2%, Hindalco dips 1%

Investors are optimistic about a possible solution between Greece and its international creditors to avert a debt crisis

Pharma shares in focus; Aurobindo Pharma hits new high

JB Chemicals, Alembic Pharma, Aurobindo Pharma, Ipca Laboratories and Dishman Pharma were up 3%-11% each.

Infinite Computer gains on board approval for share buyback proposal

The stock spurted 5% at Rs 171 after the board approved the buyback of shares at a maximum price of Rs 220 per share from the open market ...

 

Back to Top